- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.10. | CalciMedica partners with Telperian to use AI for clinical trial analysis | 1 | Investing.com | ||
| 14.10. | CalciMedica, Inc.: CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora | 119 | PR Newswire | AI tools will allow CalciMedica to analyze Phase 2 datasets to refine the target patient populations and efficacy endpoints for upcoming pivotal trials
LA JOLLA... ► Artikel lesen | |
| 12.08. | CalciMedica, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 12.08. | CalciMedica GAAP EPS of -$0.40 misses by $0.05 | 1 | Seeking Alpha | ||
| CALCIMEDICA Aktie jetzt für 0€ handeln | |||||
| 12.08. | CalciMedica, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.08. | CalciMedica, Inc.: CalciMedica Reports Second Quarter 2025 Financial Results and Provides Clinical & Corporate Updates | 132 | PR Newswire | Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) with respiratory failure; data expected in early 2026
Productive initial meeting... ► Artikel lesen | |
| 11.07. | Hedge Fund and Insider Trading News: Ken Griffin, Scott Bessent, Ray Dalio, Bill Ackman, Warren Buffett, Caxton Associates, Man Group, Calcimedica Inc (CALC), and More | 11 | Insider Monkey | ||
| 27.06. | CalciMedica, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 24.06. | CalciMedica, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 06.06. | CalciMedica ernennt Baker Tilly nach Fusion zur neuen Wirtschaftsprüfungsgesellschaft | 10 | Investing.com Deutsch | ||
| 06.06. | CalciMedica, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | CalciMedica GAAP EPS of -$0.36 misses by $0.06 | 1 | Seeking Alpha | ||
| 14.05. | CalciMedica, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | CalciMedica, Inc.: CalciMedica Reports First Quarter 2025 Financial Results and Provides Clinical & Corporate Updates | 141 | PR Newswire | Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025
Presentations at... ► Artikel lesen | |
| 27.03. | CalciMedica, Inc.: CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates | 517 | PR Newswire | Enrollment ongoing in Phase 2 KOURAGE trial of Auxora in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025
Post-hoc analysis... ► Artikel lesen | |
| 13.11.24 | CalciMedica, Inc.: CalciMedica Reports Third Quarter 2024 Financial Results and Provides Clinical & Corporate Updates | 202 | PR Newswire | Additional positive data, including a win ratio analysis, announced from CARPO Phase 2b trial of Auxora in acute pancreatitis (AP); Company expects to be in a position... ► Artikel lesen |
16 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 91,35 | +1,27 % | Turbulenzen im Biotechsektor - BioNTech, CureVac, Moderna, Vidac Pharma | Nach der stetigen Eskalation im Handelskrieg der beiden führenden Wirtschaftsnationen der Welt, USA und China, meldete der US-Finanzminister Scott Bessent, dass er zuversichtlich bezüglich des Treffens... ► Artikel lesen | |
| CUREVAC | 4,620 | -0,04 % | BionTech Aktie startet Übernahme von CureVac - Jetzt Aktien kaufen? | ||
| MODERNA | 23,695 | +0,32 % | Watch Cigna, Moderna, Reddit, and More | ||
| AMGEN | 259,05 | +0,52 % | Amgen Announces 2025 Fourth Quarter Dividend | THOUSAND OAKS, Calif., Oct. 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the... ► Artikel lesen | |
| NOVAVAX | 7,239 | -0,75 % | Novavax, Inc.: Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy | Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million... ► Artikel lesen | |
| STRYKER | 309,80 | +0,19 % | Stryker Corp. Q3 Profit Increases, Beats Estimates | WASHINGTON (dpa-AFX) - Stryker Corp. (SYK) revealed earnings for its third quarter that Increased from the same period last year and beat the Street estimates.The company's earnings came in... ► Artikel lesen | |
| BIOGEN | 134,35 | +0,30 % | Ihre wichtigsten Termine: Apple, Mastercard, Eli Lilly, Biogen, VW, Wacker Chemie und Lufthansa im Fokus! | © Foto: Jonathan Brady/PA Wire/dpa +++ dpa-Bildfunk Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine... ► Artikel lesen | |
| ILLUMINA | 107,00 | -0,41 % | Illumina, Inc.: Illumina Reports Financial Results for Third Quarter of Fiscal Year 2025 | Revenue of $1.08 billion for Q3 2025, flat compared to Q3 2024 on both a reported and constant currency basis
GAAP operating margin of 21.0% and non-GAAP operating... ► Artikel lesen | |
| MAINZ BIOMED | 1,460 | -2,67 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed to Attend 2025 Maxim Growth Summit | Issuer: Mainz BioMed N.V.
/ Key word(s): Conference
Mainz Biomed to Attend 2025 Maxim Growth Summit
15.10.2025 / 15:01 CET/CEST
The issuer is solely responsible for... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,850 | +2,53 % | Viking Therapeutics stock rises ahead of obesity drug presentations at medical conferences | ||
| INTELLIA THERAPEUTICS | 10,960 | -1,26 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) | CAMBRIDGE, Mass., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies... ► Artikel lesen | |
| TEMPUS AI | 78,00 | 0,00 % | Tempus AI (TEM) Stock Gets a $110 Price Target on Rising AI Adoption in Medicine | ||
| BIOCRYST PHARMACEUTICALS | 6,630 | +4,28 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile | - Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst's HAE portfolio - - Solidifies double digit growth trajectory for HAE... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 21,270 | +2,16 % | A Peek at Sarepta Therapeutics' Future Earnings | ||
| BIOMARIN PHARMACEUTICAL | 46,830 | +0,86 % | BioMarin Pharmaceutical Inc.: FDA Accepts BioMarin's PALYNZIQ (pegvaliase-pqpz) Supplemental Biologics License Application for Priority Review to Expand Use to Adolescents Aged 12-17 with Phenylketonuria | Application based on positive results from Phase 3 PEGASUS study, which demonstrated statistically significant blood phenylalanine (Phe) lowering compared to diet... ► Artikel lesen |
CALCIMEDICA INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,960 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CALCIMEDICA INC finden Sie auf Wallstreet Online.